Literature DB >> 20940034

New anti-HBV caryophyllane-type sesquiterpenoids from Euphorbia humifusa Willd.

Ying Tian1, Li-Min Sun, Bin Li, Xi-Qiao Liu, Jun-Xing Dong.   

Abstract

Activity-guided fractionation of Euphorbia humifusa for anti-HBV activity led to the isolation of two novel sesquiterpenoids, named humifusane A (1) and humifusane B (2). Their structures were elucidated by spectral data to show that they have a caryophyllane-type precursor structure. The two new sesquiterpenoids showed anti-HBV activities through specifically inhibiting the secretion of HBsAg in HepG2.2.15.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940034     DOI: 10.1016/j.fitote.2010.10.005

Source DB:  PubMed          Journal:  Fitoterapia        ISSN: 0367-326X            Impact factor:   2.882


  4 in total

1.  Euphorbia humifusa Willd exerts inhibition of breast cancer cell invasion and metastasis through inhibition of TNFα-induced MMP-9 expression.

Authors:  Soon Young Shin; Chang Gun Kim; You Jung Jung; Yearam Jung; Hyeryoung Jung; Jihyun Im; Yoongho Lim; Young Han Lee
Journal:  BMC Complement Altern Med       Date:  2016-10-24       Impact factor: 3.659

2.  New Bioactive Sesquiterpeniods From the Plant Endophytic Fungus Pestalotiopsis theae.

Authors:  Gaoran Liu; Ruiyun Huo; Yanan Zhai; Ling Liu
Journal:  Front Microbiol       Date:  2021-03-31       Impact factor: 5.640

Review 3.  Traditional Chinese herbal medicine as a source of molecules with antiviral activity.

Authors:  Ting Li; Tao Peng
Journal:  Antiviral Res       Date:  2012-11-12       Impact factor: 5.970

4.  In vitro antiviral activity of peptide-rich extracts from seven Nigerian plants against three non-polio enterovirus species C serotypes.

Authors:  Omonike O Ogbole; Toluwanimi E Akinleye; Abraham O Nkumah; Aminat O Awogun; Alfred F Attah; Moses O Adewumi; Adekunle J Adeniji
Journal:  Virol J       Date:  2021-08-04       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.